Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued
I'm LongbridgeAI, I can summarize articles.
Qyuns Therapeutics Co., Ltd. has initiated a share buyback program after the board determined that the stock is undervalued. The company plans to repurchase approximately 2.49 million shares, about 1.10% of its issued capital, for around HK$50.75 million, to enhance shareholder value and market confidence. Future buybacks will depend on market conditions. The current analyst rating for the stock is a Hold with a price target of HK$22.00. Qyuns Therapeutics focuses on developing therapeutic products in the healthcare sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments